List of Excipients in Branded Drug SIMCOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	SIMCOR	simvastatin and niacin	54868-5886	BUTYLATED HYDROXYANISOLE
Physicians Total Care Inc	SIMCOR	simvastatin and niacin	54868-5886	FD&C BLUE NO. 2
Physicians Total Care Inc	SIMCOR	simvastatin and niacin	54868-5886	FERROSOFERRIC OXIDE
Physicians Total Care Inc	SIMCOR	simvastatin and niacin	54868-5886	HYPROMELLOSE
Physicians Total Care Inc	SIMCOR	simvastatin and niacin	54868-5886	LACTOSE MONOHYDRATE

SIMCOR Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

SIMCOR is a fixed-dose combination of extended-release niacin and simvastatin for dyslipidemia. Its commercial value now lies less in the original brand and more in potential reformulation, generic substitution, specialty lipid products, and improved tolerability. The key development challenge is to preserve simvastatin performance while controlling niacin release, dose uniformity, tablet size, dissolution, and niacin-associated flushing.

What is SIMCOR and what drug substances does it contain?

SIMCOR combines two lipid-lowering active ingredients:

Component	Role	SIMCOR strengths
Niacin extended release	Raises HDL cholesterol and lowers triglycerides and LDL cholesterol	500 mg, 750 mg, 1,000 mg
Simvastatin	HMG-CoA reductase inhibitor that lowers LDL cholesterol	20 mg or 40 mg

The marketed strengths include 500 mg/20 mg, 750 mg/20 mg, 1,000 mg/20 mg, and 1,000 mg/40 mg tablets. SIMCOR was approved by the FDA under NDA 021366 as an extended-release niacin and simvastatin combination product.[1]

The product was developed from Abbott's Niaspan and simvastatin technology. Abbott's pharmaceutical business later became part of AbbVie. SIMCOR is no longer a major branded commercial product, and FDA records identify the product as discontinued. The discontinuation was not identified by FDA as a withdrawal for safety or efficacy reasons.[2]

What excipients are used in SIMCOR tablets?

SIMCOR uses a conventional oral solid-dose excipient system designed to support an extended-release niacin matrix and a stable simvastatin-containing tablet.

The FDA prescribing information identifies the following inactive ingredients:

• Lactose monohydrate
• Microcrystalline cellulose
• Hydroxypropyl cellulose
• Hypromellose
• Magnesium stearate
• Povidone
• Talc
• Titanium dioxide
• Iron oxide colorants

The exact colorant composition varies by strength. The combination of microcrystalline cellulose, hydroxypropyl cellulose, hypromellose, povidone, and magnesium stearate supports granulation, compression, tablet integrity, and release control.[1]

What functions do the SIMCOR excipients perform?

Excipient	Primary technical function	Commercial relevance
Lactose monohydrate	Diluent and tablet-volume contributor	Supports large-dose niacin tablets at reasonable compressibility
Microcrystalline cellulose	Diluent, dry binder, disintegration modifier	Improves compactability and tablet robustness
Hydroxypropyl cellulose	Binder and matrix modifier	Supports granule strength and release behavior
Hypromellose	Film former and release-controlling polymer	Important for sustained niacin release
Povidone	Binder and processing aid	Improves granulation and content uniformity
Magnesium stearate	Lubricant	Reduces manufacturing friction but can affect dissolution if overused
Talc	Glidant and anti-adherent	Improves powder flow and tablet manufacture
Titanium dioxide and iron oxides	Opacifiers and colorants	Support strength identification and product differentiation

The formulation problem is driven by the 500 mg to 1,000 mg niacin dose. Niacin creates a high tablet-mass burden, while simvastatin is present at a much lower dose. A substitute product must maintain content uniformity for simvastatin without compromising the niacin release profile.

What excipient strategy is most suitable for a SIMCOR generic?

A generic developer has three main formulation options.

1. Hydrophilic polymer matrix

A hydrophilic matrix based on hypromellose or a related cellulose ether is the closest technical approach to the original product. Water penetrates the matrix, the polymer hydrates, and drug diffusion and erosion control release.

Advantages include:

• Established regulatory history
• Straightforward tablet manufacturing
• Flexible control of release rate through polymer grade and concentration
• Compatibility with high-dose niacin

Key risks include:

• Dose-dependent release differences between 500 mg, 750 mg, and 1,000 mg strengths
• Sensitivity to compression force and tablet porosity
• Food-effect changes
• Potential failure to match the reference product's in vitro dissolution curve

2. Multiparticulate or coated-particle system

Niacin can be incorporated into coated granules, pellets, or mini-tablets before compression into a final dosage form. A polymer coating can provide more direct control over release than a bulk matrix.

Advantages include:

• More precise release engineering
• Potentially lower sensitivity to tablet hardness
• Better opportunity to separate niacin release from simvastatin stability requirements

The drawbacks are higher manufacturing complexity, greater process validation burden, and possible differences in pharmacokinetic behavior. A multiparticulate product may require substantial formulation and bioequivalence work.

3. Dual-phase or bilayer tablet

A bilayer tablet can physically separate the simvastatin portion from the extended-release niacin portion. This approach may improve API compatibility and allow each component to use a tailored excipient system.

Advantages include:

• Separation of incompatible microenvironments
• Independent control of simvastatin and niacin release
• Potential reduction in unnecessary polymer exposure around simvastatin

Disadvantages include:

• Higher tooling and manufacturing costs
• Greater risk of layer adhesion problems
• More complex scale-up and process controls
• Additional manufacturing variables that may affect bioequivalence

For a cost-sensitive generic, a conventional matrix tablet is likely to have the best balance of development risk and manufacturing simplicity. For a differentiated product, a multiparticulate or bilayer design offers more opportunity.

How can excipients improve niacin tolerability?

Niacin flushing is a major limitation of niacin therapy. Excipients cannot eliminate the pharmacology of niacin, but they can alter the rate and location of drug release.

Potential strategies include:

• Slower release through higher-viscosity hypromellose
• More consistent release across fed and fasted conditions
• Reduced initial release, avoiding a high early concentration
• Multiparticulate coating to distribute drug release over time
• Polymer combinations that reduce release-rate variability
• Tablet coatings that improve swallowability and adherence

A developer must avoid making unsupported therapeutic claims. Reduced flushing cannot be assumed from a slower dissolution profile alone. Clinical tolerability would depend on systemic exposure, release kinetics, patient factors, and the final product's pharmacokinetic profile.

What formulation patents protect SIMCOR?

SIMCOR's original intellectual-property position likely centered on the combination of extended-release niacin with simvastatin, including formulation, dosing, and manufacturing concepts associated with the Niaspan platform.

The relevant patent categories are:

Patent category	Potential protected subject matter	Current commercial significance
Composition patents	Niacin extended-release and simvastatin combination	Likely limited because the original product dates from 2008
Formulation patents	Polymer matrix, coating, granulation, or tablet architecture	Relevant only if an unexpired patent claim covers the proposed design
Method-of-use patents	Treatment of dyslipidemia or lipid abnormalities	Generally weak for ANDA strategy if claims are carve-out eligible
Manufacturing patents	Granulation, blending, compression, or coating methods	May affect process freedom to operate
Combination dosing patents	Specific niacin-to-simvastatin dose combinations	Commercial importance depends on claim scope and expiration

The main blocking period for an ordinary small-molecule product of this age would ordinarily have expired or become commercially nonblocking. The relevant issue for a new entrant is not the existence of historical SIMCOR patents, but whether any unexpired patent claim covers a specific formulation, manufacturing process, or method of use.

What is the Orange Book status of SIMCOR?

SIMCOR was approved under an NDA and therefore falls within the FDA's Orange Book framework. The product's commercial status is distinct from its regulatory approval history.

Regulatory issue	Assessment
NDA	021366
Dosage form	Extended-release tablet
Active ingredients	Niacin and simvastatin
FDA approval	2008
Orange Book relevance	Reference-listed drug history and patent certification framework
Current branded commercial position	Discontinued
Generic pathway	Potential ANDA pathway, subject to reference-product and bioequivalence requirements

A generic applicant would need to evaluate whether the reference product remains eligible for an ANDA strategy, whether FDA has identified a currently active reference product, and whether the proposed product must address any listed patents or exclusivity. Those determinations depend on the current Orange Book entry and FDA's discontinued-drug records.[2,3]

When does SIMCOR lose exclusivity?

The principal commercial exclusivity period for SIMCOR has ended. The product was approved more than 15 years ago, and no practical new-drug exclusivity remains for the original approval.

For a generic applicant, the remaining barriers are more likely to involve:

• Reference-product availability
• Bioequivalence to an extended-release combination product
• Historical or residual patent claims
• Manufacturing economics
• Commercial demand for a niacin-containing product
• FDA requirements for comparative dissolution and pharmacokinetic characterization

Paragraph IV risk is therefore more likely to arise from an asserted formulation or process patent than from a conventional primary composition patent. An ANDA applicant would need to make the applicable patent certification under the Hatch-Waxman framework and manage any resulting litigation exposure.[3,4]

What commercial opportunities exist for SIMCOR excipients?

Generic substitution

The most direct opportunity is a lower-cost generic version. The commercial case is limited by the decline in niacin use after large cardiovascular-outcomes studies failed to show incremental benefit when niacin was added to statin therapy in many patients.[5]

A generic can still target:

• Patients requiring combination lipid therapy
• Patients with mixed dyslipidemia
• Prescribers seeking a fixed-dose product
• Markets where niacin remains clinically accepted
• Health systems seeking lower-cost alternatives to separate tablets

Reformulated combination product

A reformulated product could compete on:

• Lower tablet burden
• Improved swallowability
• Better dissolution consistency
• Lower excipient load
• Reduced sensitivity to food intake
• Easier titration across niacin strengths

A new product would need a clear regulatory strategy. Depending on the formulation and claims, the developer could consider an ANDA, a 505(b)(2) application, or a nonprescription development strategy only if the regulatory and labeling requirements were satisfied. A materially different release system or clinical claim would increase 505(b)(2) relevance.

Separate-component packaging

A commercial alternative is a co-pack containing extended-release niacin and simvastatin as separate tablets. This approach avoids some fixed-dose formulation complexity and permits independent dose adjustment.

Its disadvantages are reduced convenience, weaker product differentiation, and possible substitution by inexpensive generic simvastatin and generic niacin products.

Excipient-enabled lifecycle product

A differentiated product could use:

• A smaller high-load tablet
• A bilayer architecture
• A sprinkle or dispersible format, if technically and regulatorily viable
• A polymer system designed for more consistent fed and fasted release
• A film coating that improves handling and swallowability

The strongest opportunity is a product that demonstrates a measurable adherence or tolerability advantage, not merely a different excipient list.

How strong is the SIMCOR patent estate?

The original SIMCOR estate is commercially weak relative to newer branded medicines because the product launched in 2008 and its core exclusivity period has passed. Patent risk remains relevant for a new formulation but is unlikely to support a broad branded barrier without a genuinely novel release system or manufacturing process.

Factor	Assessment
Core composition protection	Low current value
Extended-release formulation protection	Potentially relevant, claim-specific
Method-of-use protection	Limited commercial leverage
Manufacturing protection	Relevant to freedom-to-operate
Regulatory exclusivity	Expired
Generic entry risk	High if reference and bioequivalence requirements can be satisfied
Reformulation opportunity	Moderate, but dependent on clinical demand

What generic launch scenarios exist?

Scenario 1: Conventional ANDA

A developer uses a matrix tablet and demonstrates pharmaceutical equivalence and bioequivalence. This is the lowest-cost route but faces limited market demand and possible manufacturing complexity.

Scenario 2: 505(b)(2) reformulation

A developer introduces a substantially different release system or dosage form and relies partly on FDA findings for the approved product. This offers more differentiation but requires a stronger clinical and regulatory package.

Scenario 3: Regional launch

A company targets markets where niacin remains commonly used or where fixed-dose combination products have stronger reimbursement support. Regional manufacturing and licensing can reduce launch costs.

Scenario 4: Licensing or asset acquisition

A company with an existing niacin or statin platform could license a SIMCOR-compatible formulation, manufacturing process, or regional dossier. The main diligence issues would be patent clearance, reference-product access, stability data, and commercial demand.

What manufacturing and IP barriers matter most?

The main barriers are technical rather than exclusivity-based:

1. Achieving comparable extended-release dissolution.
2. Controlling simvastatin content uniformity at a low dose.
3. Preventing segregation in a high-dose niacin blend.
4. Managing lubricant effects on release and tablet strength.
5. Demonstrating stability of simvastatin and niacin in the same dosage form.
6. Scaling a large tablet without capping, lamination, or poor dissolution.
7. Establishing food-effect and pharmacokinetic comparability.
8. Avoiding unexpired claims covering a particular polymer system or process.

Key Takeaways

• SIMCOR combines extended-release niacin with simvastatin in four tablet strengths.
• Its excipient system relies on lactose, microcrystalline cellulose, cellulose polymers, povidone, magnesium stearate, talc, and colorants.
• A hydrophilic hypromellose matrix is the most practical generic formulation strategy.
• Bilayer and multiparticulate designs offer greater differentiation but carry higher development risk.
• Original regulatory exclusivity has ended, and the main entry barriers are bioequivalence, manufacturing, market demand, and any residual formulation patents.
• The best commercial opportunity is a technically differentiated product that improves dose handling, tablet burden, or release consistency.
• The market case is constrained by reduced clinical use of niacin in combination with statins after outcome-trial results.

FAQs

Is SIMCOR still marketed in the United States?

FDA records identify SIMCOR as discontinued. The product's approval history remains relevant for regulatory and reference-product analysis.

Can a generic manufacturer copy SIMCOR's excipients?

A generic manufacturer may use different inactive ingredients if the product meets applicable FDA requirements for pharmaceutical equivalence, bioequivalence, safety, quality, and labeling.

Is hypromellose essential to a SIMCOR generic?

No. Hypromellose is a logical release-controlling polymer, but other polymers or multiparticulate systems may be used if the finished product demonstrates comparable performance.

Could a SIMCOR reformulation qualify for new patent protection?

Potentially. A genuinely novel polymer system, bilayer design, manufacturing process, or release profile may support patent claims, provided the invention satisfies novelty, nonobviousness, written-description, and enablement requirements.

Why is SIMCOR commercially less attractive than a standard statin?

Niacin use declined after clinical evidence showed limited incremental cardiovascular benefit when added to effective statin therapy in many patients. That reduces the addressable market for a fixed-dose niacin-statin product.[5]

References

1. U.S. Food and Drug Administration. (2008). SIMCOR (niacin extended-release and simvastatin) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). FDA-approved drug products and discontinued drug product records.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. Boden, W. E., Probstfield, J. L., Anderson, T., et al. (2011). Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine, 365(24), 2255-2267.